Reproducibility and Reliability of Experimental Results Confirmed Across Institutions

International Validation of Key Markers for Identifying the Undifferentiated State

The Korea Disease Control and Prevention Agency and the National Institute of Health announced on March 19 that the results of a multinational, multi-institutional international joint study on standardizing the quality of induced pluripotent stem cells (iPSCs) will be published in an international academic journal.


This study was an international collaborative effort involving research institutions from 12 countries, conducted to establish cell quality evaluation criteria necessary for the development of stem cell therapeutics.

National Institute of Health Establishes International Standards for Stem Cell Quality Assessment View original image

The research team carried out a joint quality assessment study, in which multinational and multi-institutional teams analyzed stem cells using the same methodology. As a result, they confirmed that applying standardized analytical methods significantly improved the reproducibility and reliability of experimental results across different institutions. In particular, OCT3/4, TRA-1-60, and SSEA5 proteins were identified as the most stable and reproducible key markers for verifying the undifferentiated state—when stem cells have not yet transformed into other cell types.


Through this study, the National Institute of Health has contributed to ensuring the safety of iPSCs for clinical applications and to the standardization of global manufacturing and quality evaluation criteria. The institute also plans to continue expanding international cooperation based on the National Stem Cell Bank in the future.



Wonho Kim, Director of the Department of Convergence Research for Chronic Disease at the National Institute of Health, stated, "This research is a meaningful achievement in establishing international quality standards for iPSC-based therapeutics and will serve as an important foundation for enhancing the global competitiveness of domestic regenerative medicine technology." He added, "We will continue to actively promote international joint research and the advancement of quality management in the field of advanced regenerative medicine."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing